Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CFO Sells $139,304.96 in Stock

Key Points

• Zai Lab's CFO, Yajing Chen, sold 4,096 shares of the company's stock for approximately $139,304.96, resulting in a 19.50% decrease in ownership.
• Following the recent stock trades, Zai Lab's share price fell to $34.31, down from a 12-month high of $44.34, indicating significant volatility in its market performance.
• Research analysts maintain a Moderate Buy consensus rating for Zai Lab, with price targets ranging from $57.22 to $75.00.

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) CFO Yajing Chen sold 4,096 shares of the business's stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $34.01, for a total transaction of $139,304.96. Following the completion of the transaction, the chief financial officer directly owned 16,908 shares in the company, valued at $575,041.08. This trade represents a 19.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Yajing Chen also recently made the following trade(s):

• On Thursday, June 26th, Yajing Chen sold 2,675 shares of Zai Lab stock. The shares were sold at an average price of $36.13, for a total transaction of $96,647.75.
• On Monday, June 2nd, Yajing Chen sold 9,618 shares of Zai Lab stock. The shares were sold at an average price of $30.00, for a total transaction of $288,540.00.

Zai Lab Price Performance

NASDAQ ZLAB traded down $0.35 during trading hours on Tuesday, hitting $34.31. The company's stock had a trading volume of 394,193 shares, compared to its average volume of 995,971. Zai Lab Limited Unsponsored ADR has a 12 month low of $16.01 and a 12 month high of $44.34. The company's 50 day simple moving average is $36.70 and its two-hundred day simple moving average is $33.36. The company has a market cap of $3.81 billion, a P/E ratio of -16.82 and a beta of 1.03.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.37). The business had revenue of $109.98 million during the quarter, compared to the consensus estimate of $125.66 million. Zai Lab had a negative return on equity of 27.32% and a negative net margin of 49.68%. As a group, research analysts predict that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Citigroup reissued a "buy" rating and issued a $69.00 price target (up from $66.00) on shares of Zai Lab in a report on Monday. Leerink Partners set a $75.00 price target on shares of Zai Lab and gave the stock an "outperform" rating in a report on Monday, June 30th. Finally, Wall Street Zen downgraded shares of Zai Lab from a "buy" rating to a "hold" rating in a report on Friday, June 27th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $57.22.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Acadian Asset Management LLC purchased a new stake in shares of Zai Lab during the 1st quarter worth approximately $1,073,000. MPM Bioimpact LLC raised its holdings in shares of Zai Lab by 4.2% during the 1st quarter. MPM Bioimpact LLC now owns 833,659 shares of the company's stock worth $30,128,000 after acquiring an additional 33,659 shares in the last quarter. Frazier Life Sciences Management L.P. purchased a new stake in shares of Zai Lab during the 1st quarter worth approximately $12,649,000. Cubist Systematic Strategies LLC raised its holdings in shares of Zai Lab by 29.0% during the 1st quarter. Cubist Systematic Strategies LLC now owns 93,645 shares of the company's stock worth $3,384,000 after acquiring an additional 21,026 shares in the last quarter. Finally, Royal Bank of Canada raised its holdings in shares of Zai Lab by 214.3% during the 1st quarter. Royal Bank of Canada now owns 13,771 shares of the company's stock worth $498,000 after acquiring an additional 9,390 shares in the last quarter. 41.65% of the stock is owned by hedge funds and other institutional investors.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.